News of the milestone comes a month and a half after the Boston-based company announced a $55 million Series D round.
Invasive fractional flow reserve (FFR), the ground truth for FFR-IQ, uses a pressure wire during cardiac catheterization to determine whether a narrowing in a coronary artery is limiting blood flow, potentially requiring a coronary artery stent or bypass. By estimating FFR noninvasively, FFR-IQ helps physicians identify which patients are likely to benefit from invasive evaluation and treatment, potentially avoiding most unnecessary catheterizations.